![Amy Chappell](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Amy Chappell
Directeur/Bestuurslid bij
BIOVIE INC.
Vermogen: 1 105 $ op 30-09-2026
Profiel
Amy S.
Chappell is currently an Independent Director at BioVie, Inc. since 2025 and Chief Medical Officer at Solaxa, Inc. since 2024.
Formerly, Dr. Chappell was Chief Medical Officer at Climb Bio, Inc. from 2020 to 2021.
Education includes undergraduate studies at Antioch College and a doctorate from The Indiana University School of Medicine.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
BIOVIE INC. CLASS A 0,01% | 31-08-2026 | 727 ( 0,01% ) | 1 105 $ | 30-09-2026 |
Actieve functies van Amy Chappell
| Bedrijven | Functie | Begin |
|---|---|---|
| BIOVIE INC. | Directeur/Bestuurslid | 22-07-2025 |
Eerdere bekende functies van Amy Chappell
| Bedrijven | Functie | Einde |
|---|---|---|
| CLIMB BIO, INC. | Hoofd Techniek/Wetenschap/O&O | 31-12-2021 |
Opleiding van Amy Chappell
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
20
Eerstegraads connecties
4
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
BioVie, Inc.
 BioVie, Inc. BiotechnologyHealth Technology Develops drug therapies for chronic debilitating conditions | Health Technology |
Antioch College
 Antioch College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Indiana University School of Medicine
 The Indiana University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Eliem Therapeutics, Inc.
 Eliem Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders | Health Technology |
